Michael McDonald

Michael McDonald

Auto-generated profile, based on publicly available information

Michael McDonald

Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
MMMichael McDonald
Michael McDonald
SVSean Virani
Sean Virani
MCMichael Chan
Michael Chan
ADAnique Ducharme
Anique Ducharme
JEJustin A. Ezekowitz
Justin A. Ezekowitz
AYAmelia Ming Ching Yip
Amelia Ming Ching Yip

1 October 2021 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
ALAdriana Luk
Adriana Luk
BCBrian Clarke
Brian Clarke
NDNagib Dahdah
Nagib Dahdah
ADAnique Ducharme
Anique Ducharme
AKAndrew Krahn
Andrew Krahn
MMMichael McDonald
Michael McDonald

17 March 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
Javier Tomas Solera RalloJavier Tomas Solera Rallo
Javier Tomas Solera Rallo
BÁBerta G. Árbol
Berta G. Árbol
AMAnkit Mittal
Ankit Mittal
VHVictoria Hall
Victoria Hall
TMTina Marinelli
Tina Marinelli
DKDeepali Kumar
Deepali Kumar
Data regarding COVID-19 outcomes in solid organ transplant recipients(SOTr) across SARS-CoV-2 waves, including the impact of different measures, is lacking. This cohort study, conducted from March 2020-May 2023 in Toronto, Canada, aimed to analyze COVID-19 outcomes in 1,975 SOTr across various SARS-CoV-2 waves and assess the impact of preventive and treatment measures. The primary outcome was severe COVID-19, defined as requiring supplemental oxygen, with secondary outcomes including hospitalization, length of stay, ICU admission, and 30-day and 1-year all-cause mortality. SARS-CoV-2 waves were categorized as Wildtype/Alpha/Delta(318 cases, 16.1%), Omicron-BA.1(268, 26.2%), Omicron-BA.2(268, 13.6%), Omicron-BA.5(561, 28.4%), Omicron-BQ.1.1(188, 9.5%), and Omicron-XBB.1.5(123, 6.2%). Severe COVID-19 rate was highest during the Wildtype/Alpha/Delta wave(44.6%), and lower in Omicron waves(5.7-16.1%). Lung transplantation was associated with severe COVID-19(OR:4.62, 95%CI:2.71-7.89), along with rituximab treatment(OR:4.24, 95%CI:1.04-17.3), long-term corticosteroid use(OR:3.11, 95%CI:1.46-6.62), older age(OR: 1.51, 95%CI:1.30-1.76), chronic lung disease(OR:2.11, 95%CI:1.36-3.30), chronic kidney disease(OR:2.18, 95%CI:1.17-4.07), and diabetes(OR:1.97, 95%CI:1.37-2.83). Early treatment and ≥3 vaccine doses were associated with reduced severity(OR: 0.29, 95%CI:0.19-0.46, and 0.35, 95%CI:0.21-0.60, respectively). Tixagevimab/cilgavimab and bivalent boosters did not show a significant impact. The study concludes that COVID-19 severity decreased across different variants in SOTr. Lung transplantation was associated with worse outcomes and may benefit more from preventive and early therapeutic interventions.

22 January 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SWSahr Wali
Sahr Wali
MMMilena Guessi Margarido
Milena Guessi Margarido
ASAmika Shah
Amika Shah
PWPatrick Ware
Patrick Ware
MMMichael McDonald
Michael McDonald
ESEmily Seto
Emily Seto
Background: To minimize the spread and risk of a COVID-19 outbreak, societal norms have been challenged with respect to how essential services are delivered. With pressures to reduce the number of in-person ambulatory visits, innovative models of telemonitoring have been used during the pandemic as a necessary alternative to support access to care for patients with chronic conditions. The pandemic has led health care organizations to consider the adoption of telemonitoring interventions for the first time, while others have seen existing programs rapidly expand. Objective: At the Toronto General Hospital in Ontario, Canada, the rapid expansion of a telemonitoring program began on March 9, 2020, in response to COVID-19. The objective of this study was to understand the experiences related to the expanded role of a telemonitoring program under the changing conditions of the pandemic. Methods: A single-case qualitative study was conducted with 3 embedded units of analysis. Semistructured interviews probed the experiences of patients, clinicians, and program staff from the Medly telemonitoring program at a heart function clinic in Toronto, Canada. Data were analyzed using inductive thematic analysis as well as Eakin and Gladstone’s value-adding approach to enhance the analytic interpretation of the study findings. Results: A total of 29 participants were interviewed, including patients (n=16), clinicians (n=9), and operational staff (n=4). Four themes were identified: (1) providing care continuity through telemonitoring; (2) adapting telemonitoring operations for a more virtual health care system; (3) confronting virtual workflow challenges; and (4) fostering a meaningful patient-provider relationship. Beyond supporting virtual visits, the program’s ability to provide a more comprehensive picture of the patient’s health was valued. However, issues relating to the lack of system integration and alert-driven interactions jeopardized the perceived sustainability of the program. Conclusions: With the reduction of in-person visits during the pandemic, virtual services such as telemonitoring have demonstrated significant value. Based on our study findings, we offer recommendations to proactively adapt and scale telemonitoring programs under the changing conditions of an increasingly virtual health care system. These include revisiting the scope and expectations of telemedicine interventions, streamlining virtual patient onboarding processes, and personalizing the collection of patient information to build a stronger virtual relationship and a more holistic assessment of patient well-being.

1 April 2004 in International braz j urol
Verified
Journal Article
Open access
PDF file
MMMichael Mcdonald
Michael Mcdonald
RSRichard A. Santucci
Richard A. Santucci
Low-flow priapism can result in impotence if treatment is delayed, yet patients with recurrent priapism often suffer delay before therapy. We describe management of recurrent priapism using self-administered injections of intracavernosal metaraminol (Aramine, Merck), a long-acting vasoconstricting amine that is considered safer than epinephrine. The patient injects as often as once daily using 5-10 mg of drug. Our patient reports rapid detumescence and has not required emergency room visits since starting injections. He denies complications. Treatment of priapism using metaraminol has been suggested in the hospital setting; however, this is the first report of successful home self-administration of the drug.

5 September 2017 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
MMMichael A. McDonald
Michael A. McDonald
EAEuan A. Ashley
Euan A. Ashley
PFPaul Fedak
Paul Fedak
NHNathaniel Hawkins
Nathaniel Hawkins
JJJames L. Januzzi
James L. Januzzi
SVSean Virani
Sean Virani